Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4752W HIGH $2.19
Volume
44.52 K
Value Traded
215.37 K
Short % Float
20.63%
-6.7%Week
-14.78%1 Month
-14.88%3 Month
-38.39%6 Month
-98.74%5 Year
-99.81%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
13.73 M
EPS (TTM)
-2.12
P/E Ratio
-
Ent. Value
-3.39 M
Total Shares
27.44 M
Float Shares
26.96 M
Insiders
1.80%
Institutions
4.95%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CTXR Catalyst Timeline
Dated clinical, regulatory and corporate events for Citius Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Citius Pharmaceuticals, Inc.
394Total events
1Upcoming
104Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 1
TBD
T2FDA Feedback Received
Subscribe to view catalyst details
Event history 50
▲Quarterly UpdateLYMPHIRApprovedCorporate
Nationwide deployment of expanded commercial and medical affairs teams completed
▲Quarterly UpdateLYMPHIRApprovedCorporate
383 vials ordered in July 2026, largest month to date
◆Poster PresentationLYMPHIRApprovedPresentation
Phase 1 data of LYMPHIR + pembrolizumab presented at ASCO 2026
recurrent or refractory gynecologic malignanciessource ↗
●Quarterly UpdateCorporate
Citius Pharma reports fiscal Q2 2026 financial results and business update
▲Debt Royalty FinancingCorporate
Citius Oncology secured up to $36.5 million in debt and equity financing
▲Topline ReadoutLYMPHIRApprovedClinical Data
Positive preliminary topline Phase 1 data from two investigator-initiated combination studies with LYMPHIR
CTCL (combination with pembrolizumab and prior to CAR-T)source ↗
◆FDA Feedback ReceivedMino-LokFiledFDA Meeting
Citius Pharma actively engaged with FDA to outline next steps for Mino-Lok
catheter-related bloodstream infectionssource ↗
◆FDA Feedback ReceivedCombination- CITI-002FDA Meeting
Citius Pharma actively engaged with FDA to outline next steps for Halo-Lido
hemorrhoidssource ↗
▲Product LaunchLYMPHIRApprovedPost-Market
Initial shipment of LYMPHIR to Europe through regional distribution partner
relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL)source ↗
▲Topline ReadoutLYMPHIRApprovedClinical Data
Positive topline results from Phase 1 study of LYMPHIR in combination with pembrolizumab
relapsed or refractory gynecologic cancerssource ↗
▲Topline ReadoutLYMPHIRApprovedClinical Data
Preliminary topline Phase 1 data of LYMPHIR prior to CAR-T therapy in DLBCL
high-risk relapsed or refractory diffuse large B-cell lymphomasource ↗
●Oral PresentationLYMPHIRApprovedPresentation
Full results presented at 2026 ASTCT & CIBMTR Tandem Meetings
high-risk relapsed or refractory diffuse large B-cell lymphomasource ↗
▲Oral PresentationLYMPHIRApprovedPresentation
Phase 1 data presented at ASCO 2026 for LYMPHIR + pembrolizumab
recurrent or refractory gynecologic malignanciessource ↗
▲Trial CompletionLYMPHIRApprovedTrial
Phase I study of LYMPHIR + pembrolizumab in solid tumors completed at UPMC
solid tumorssource ↗
▲Partnership / LicenseLYMPHIRApprovedCorporate
Distribution agreements executed across Europe and Middle East for LYMPHIR
◆Topline ReadoutLYMPHIRApprovedClinical Data
Preliminary study results of LYMPHIR + CAR T therapy anticipated
high risk relapsed/refractory B-cell lymphomassource ↗
▲Product LaunchLYMPHIRApprovedPost-Market
LYMPHIR launched in December 2025
relapsed or refractory Stage I-III CTCLsource ↗
▲FDA ApprovalLYMPHIRApprovedFDA Decision
FDA approval of LYMPHIR
relapsed or refractory Stage I-III cutaneous T-cell lymphomasource ↗
▲Interim AnalysisLYMPHIRApprovedTrial
Interim analysis of LYMPHIR + KEYTRUDA combination trial shows 27% ORR, 33% CBR, median PFS 57 weeks
recurrent or metastatic solid tumorssource ↗
▲Partnership / LicenseLYMPHIRApprovedCorporate
Exclusive distribution agreement with Integris Pharma S.A. for 12 markets
◆Product LaunchLYMPHIRApprovedPost-Market
Planned U.S. launch of LYMPHIR in Q4 2025
cutaneous T-cell lymphomasource ↗
▲Interim AnalysisLYMPHIRApprovedTrial
Interim analysis of LYMPHIR + KEYTRUDA combination study: 27% ORR, 33% CBR, median PFS 57 weeks
recurrent or metastatic solid tumorssource ↗
◆Topline ReadoutLYMPHIRApprovedClinical Data
Phase 1 preliminary study data anticipated Q4 2025/Q1 2026
recurrent or metastatic solid tumorssource ↗
▼Equity OfferingCorporate
Registered direct offering of up to $15.8 million priced at-the-market
▼Runway Guidance UpdateCorporate
Cash runway guidance: need additional capital beyond May 2025
▲Product LaunchLYMPHIRApprovedPost-Market
Permanent J-code (J9161) effective for LYMPHIR
relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapysource ↗
▼Equity OfferingCorporate
Registered direct offering of 743,496 shares and warrants at $4.035 per unit for $3 million gross proceeds
▲FDA ApprovalLYMPHIRApprovedFDA Decision
FDA approval of LYMPHIR
relapsed or refractory Stage I–III CTCLsource ↗
◆Product LaunchLYMPHIRApprovedPost-Market
U.S. market launch of LYMPHIR within five months
relapsed or refractory cutaneous T-cell lymphomasource ↗
▲Type C MeetingMino-LokFiledFDA Meeting
Productive FDA Type C meeting to discuss Phase 3 Mino-Lok program and pathway to approval
catheter-related bloodstream infectionssource ↗
Past FDA Catalysts and PDUFA Decisions
How CTXR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-08-08 | LYMPHIR (denileukin diftitox) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F12 / 100
Pipeline Score
$0M
Pipeline Value
$7M
Commercial Value
Overvalued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 99%
Micro Cap(rank 651 of 658)
Percentile Rank
Citius Pharmaceuticals, Inc. has significant pipeline risk (12/100), with $146M risk-adjusted pipeline value, led by Monad 1 in Hemorrhoids (Phase 2), but cash runway is a concern.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $7.1M x 1.0 = $7M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| LYMPHIR | $7M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Monad 1 Small moleculeCompletedNCT05348200 | Hemorrhoids | Phase 2 | COMPLETED | 304 | May 17, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every CTXR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LYMPHIR (denileukin diftitox-cxdl) | recurrent or refractory gynecologic malignancies | Phase 1 | 2026-05-30 | median progression free survival: 20.5 months; clinical benefit: 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21); objective response rate: 33% in patients with relapsed or refractory endometrial cancerRead More | Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Investigator-initiateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Holuka Eugene MyronDirector | Option | 2,415 2,415 held | $0.02 | 03/13/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in CTXR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CTXR for Q2 2026. | ||||
CTXR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CTXR ranks across every disease it competes in
Competitive Position is a premium feature
See how CTXR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCTXR News
CTXRCitius Pharmaceuticals to Participate in September 2026 Investor Conferences
Citius Pharmaceuticals announced that CEO Leonard Mazur will present at two investor conferences in September 2026. The presentations will cover the company's ongoing commercialization of LYMPHIR and advancements in its late-stage pipeline. The conferences will take place in New York City, with specific dates and times for each event provided.
Read more →CTXR▼ -25.6%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals reported its fiscal third quarter 2026 results, highlighting $7.1 million in revenue driven by LYMPHIR's commercial success. The company expanded its commercial teams and reported positive clinical data for LYMPHIR in various malignancies. However, it also faced a net loss of $8.9 million, reflecting increased operational costs.
Read more →CTXRCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Citius Oncology has highlighted promising Phase 1 data from an investigator-initiated study of LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab for patients with recurrent or refractory gynecologic malignancies. The study, presented at the American Society of Clinical Oncology Annual Meeting, reported a 20.5-month median progression-free survival and notable responses in heavily pre-treated patients. While the safety profile was manageable, LYMPHIR is not approved for this indication, and its effects are still being evaluated. The company plans further clinical studies to expand understanding of this combination therapy in gynecologic cancers.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. reported financial results for the fiscal second quarter of 2026, highlighting $5.6 million in net revenue from the commercial launch of LYMPHIR. The company noted that 83% of target accounts have either been included on formularies or are under review, with payer coverage reaching near 100% for commercial lives. Additionally, Citius Oncology secured $36.5 million in financing to support its commercial activities, while positive Phase 1 data further bolstered the potential of LYMPHIR in combination treatments. The report reflects significant strides in establishing a sustainable market presence.
Read more →CTXR▼ -8.5%on this news
Citius Oncology Ships First International Order of LYMPHIR to Europe
Citius Oncology has successfully shipped LYMPHIR (denileukin diftitox-cxdl) to Europe, marking a significant milestone in expanding treatment access for patients with cutaneous T-cell lymphoma. The therapy will be made available through Named Patient Programs, adhering to local regulations. This international order follows the treatment's initial U.S. launch and demonstrates the company's commitment to providing options in markets where alternatives are limited. LYMPHIR is approved for patients with Stage I-III relapsed or refractory disease after prior systemic therapy.
Read more →CTXR▼ -17.5%on this news· ran to -36% by day 3shared move
Citius Pharmaceuticals Announces a Registered
Citius Pharmaceuticals Inc. has announced a registered direct offering of approximately $5 million through the purchase of over 5 million shares of its common stock. This offering is priced at-the-market under Nasdaq rules and is part of a broader strategy to support the commercial launch of LYMPHIR and further development of other pipeline candidates. The transaction is subject to customary closing conditions and is expected to close on approximately April 24, 2026.
Read more →CTXR▼ -17.5%on this news· ran to -36% by day 3shared move
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals has announced the closing of a registered direct offering, raising approximately $5 million. The funds will be utilized to support the commercial launch of its product LYMPHIR, along with other development initiatives. The offering included the sale of common stock and unregistered warrants, with H.C. Wainwright & Co. acting as the placement agent.
Read more →CTXR▲ +32.3%on this news
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology has provided a commercial update on the U.S. launch of LYMPHIR, an FDA-approved treatment for cutaneous T-cell lymphoma. The update highlights significant early adoption among oncology centers and expanding payer coverage, which support the therapy's uptake. The company is also advancing clinical development through collaborations with prominent academic institutions to explore LYMPHIR's potential in broader oncology applications. Initial market projections indicate that the demand for LYMPHIR is substantial, with ongoing efforts to establish a strong commercial presence and educational outreach to care providers.
Read more →CTXR▲ +11%on this news
Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology announced positive topline results from an investigator-initiated Phase 1 study of LYMPHIR combined with pembrolizumab for patients with relapsed or refractory gynecologic cancers. Conducted by the University of Pittsburgh, the study revealed a 24% objective response rate and a favorable safety profile. The findings indicate potential augmented efficacy of the combined therapy, warranting further investigation in Phase 2 trials. Results will be presented at an upcoming international cancer conference.
Read more →CTXR▲ +10.3%on this news· ran to +28% by day 1
Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell Lymphoma
Citius Oncology has announced positive preliminary results from a Phase 1 trial of LYMPHIR (E7777) in patients with high-risk diffuse large B-cell lymphoma (DLBCL), demonstrating an 86% overall response rate. The trial showed no dose-limiting toxicities, indicating a favorable safety profile. These encouraging findings suggest that LYMPHIR could enhance the effectiveness of existing CAR-T therapies, particularly in patients exhibiting poor prognostic features. The first results were presented at the 2026 ASTCT & CIBMTR Tandem Meetings.
Read more →CTXR▲ +12.7%on this news
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Citius Pharmaceuticals has secured $3.8 million in non-dilutive capital through New Jersey's NOL Program. This funding will support the commercial launch of LYMPHIR and advance its late-stage pipeline programs. The CFO emphasized the importance of this capital for enhancing the company's financial flexibility and long-term shareholder value.
Read more →CTXRCitius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Pharmaceuticals, Inc. announced its first reported revenue following the successful launch of LYMPHIR, generating $3.9 million in sales during the fiscal first quarter ending December 31, 2025. The company, which focuses on critical care products, expressed optimism about future growth opportunities, including expanding access to their therapies. CEO Leonard Mazur highlighted the significance of LYMPHIR as a new treatment option for patients with relapsed or refractory cutaneous T-cell lymphoma. Additionally, the company is committed to advancing its late-stage pipeline.
Read more →CTXRCitius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Pharmaceuticals announced its first reported revenue of $3.9 million following the launch of LYMPHIR for cutaneous T-cell lymphoma. The company is optimistic about future growth, citing early physician adoption and international access initiatives. However, it also reported a net loss of $8.2 million, indicating ongoing financial challenges. The company remains focused on advancing its late-stage pipeline.
Read more →CTXR▼ -23%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals reported its fiscal year 2025 results, highlighting the successful launch of LYMPHIR, an FDA-approved immunotherapy for CTCL patients. The company aims to drive adoption of LYMPHIR in 2026 while exploring further indications and markets. Citius is also focused on strengthening its financial foundation and advancing its late-stage pipeline products.
Read more →CTXR▼ -6.2%on this news
NASDAQ: CTXR Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Corporate Overview DECEMBER 2025 FORWARD - LOOKING STATEMENTS NASDAQ: CTXR 2 This presentation has been prepared by Citius Pharmaceuticals, Inc . (the "Company") f
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) recently provided a corporate overview highlighting its strategic initiatives and future plans. The company has launched LYMPHIR, a new treatment for relapsed or refractory Stage I-III cutaneous T-cell lymphoma, enhancing its oncology portfolio. Additionally, they reported positive results from the Mino-Lok Phase 3 trial. However, they acknowledge substantial funding needs and potential risks in commercialization and operational execution.
Read more →CTXR▲ +9.6%on this news
This presentation has been prepared by Citius Pharmaceuticals, Inc . (the "Company") for informational purposes only and not for any other purpose . Nothing contained in this presentation is, or should be construed as, a
Citius Pharmaceuticals, Inc. has presented an overview outlining its plans for commercializing LYMPHIR, a treatment for cutaneous T-cell lymphoma (CTCL), which received FDA approval in August 2024. The company has invested over $90 million to prepare for the anticipated launch in Q4 2025, focusing on various pre-commercial activities including inventory manufacturing and supply chain agreements. Citius also highlights its strategic partnerships and the expected market demand, forecasting significant opportunities in the treatment of CTCL.
Read more →CTXR▼ -7.2%on this newsshared move
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals announced the closing of a registered direct offering, raising approximately $6.0 million. The offering included 3,973,510 shares priced at $1.51 each, with accompanying common warrants. The proceeds will be used to support the launch of LYMPHIR™, alongside other development initiatives. H.C. Wainwright & Co. acted as the exclusive placement agent.
Read more →About Citius Pharmaceuticals, Inc.
Headquarters11 COMMERCE DRIVE, CRANFORD, NJ, 07016
BIOPHARMAWATCH ELITE PLUS
Trade the next CTXR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime